IP Library Granted Patent US 11,098,052
Granted Patent B2
US 11,098,052 · App. 16/081,683 · Granted Aug 24, 2021

4-azapodophylotoxins compounds

Inventors: George Robert Pettit (Paradise Valley, AZ); Justin Searcy (Loveland, CO)
Assignee: Arizona Board of Regents on behalf of Arizona State University
C07D491/048A61P35/00C07D491/14C07D491/153
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,098,052
App. No.
16/081,683
Granted
Aug 24, 2021
Kind
B2
Abstract

The present disclosure relates to 4-azapodophylotoxins compounds, pharmaceutical compositions comprising such compounds, kits, and methods for using such compounds or pharmaceutical compositions.

Claims (18)

1. A compound selected from the group consisting of:

6,7-Methylenedioxy-4-(cyclobutyl)-9-(3,4,5-trimethoxyphenyl)-4,9-dihydro-3H-furo[3,4-b]quinolin-1-one (Compound 17);

6,7-Methylenedioxy-4-(cyclopentyl)-9-(3,4,5-trimethoxyphenyl)-4,9-dihydro-3H-furo[3,4-b]quinolin-1-one (Compound 18);

6,7-Methylenedioxy-4-(cyclohexyl)-9-(3,4,5-trimethoxyphenyl)-4,9-dihydro-3H-furo[3,4-b]quinolin-1-one (Compound 19);

6,7-Methylenedioxy-4-(2-piperidin-1-yl-ethyl)-9-(3,4,5-trimethoxyphenyl)-4,9-dihydro-3H-furo[3,4-b]quinolin-1-one (Compound 21);

6,7-Methylenedioxy-4-(2-morpholin-4-yl-ethyl)-9-(3,4,5-trimethoxyphenyl)-4,9-dihydro-3H-furo[3,4-b]quinolin-1-one (Compound 22);

6,7-Methylenedioxy-4-(cyclopentyl)-9-(4-hydroxy-3,5-dimethoxy-phenyl)-4,9-dihydro-3H-furo[3,4-b]quinolin-1-one (Compound 30);

and

a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

3. A method for treating cancer in a patient in need thereof comprising administering to the patient a compound of claim 1 , wherein the compound is administered in an amount effective to treat cancer.

4. The compound of claim 1 , wherein the compound is selected from the group consisting of:

6,7-Methylenedioxy-4-(cyclobutyl)-9-(3,4,5-trimethoxyphenyl)-4,9-dihydro-3H-furo[3,4-b]quinolin-1-one (Compound 17);

6,7-Methylenedioxy-4-(cyclopentyl)-9-(3,4,5-trimethoxyphenyl)-4,9-dihydro-3H-furo[3,4-b]quinolin-1-one (Compound 18);

6,7-Methylenedioxy-4-(cyclohexyl)-9-(3,4,5-trimethoxyphenyl)-4,9-dihydro-3H-furo[3,4-b]quinolin-1-one (Compound 19);

6,7-Methylenedioxy-4-(cyclopentyl)-9-(4-hydroxy-3,5-dimethoxy-phenyl)-4,9-dihydro-3H-furo[3,4-b]quinolin-1-one (Compound 30);

and

a pharmaceutically acceptable salt thereof.

Assignments (2)
CONFIRMATORY LICENSE Recorded Dec 3, 2019
From: ARIZONA STATE UNIVERSITY TEMPE CAMPUS
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 051227/0848 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2018
From: SEARCY, JUSTIN; PETTIT, GEORGE ROBERT
To: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
Reel/Frame 046835/0573 →
Continuity (2)
Provisional Application 62302236 · Mar 2, 2016
Related Publication 20190077808A1 · Mar 14, 2019